Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia

NCT04103879 is registered in ClinicalTrials.gov with ExCellThera inc. as lead sponsor.

NCT NCT04103879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04103879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study of UM171-Expanded Cord Blood Transplantation in Patients With High and Very High Risk Acute Leukemia/Myelodysplasia
Lead sponsor
ExCellThera inc.
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2020
Completion date
February 28, 2026
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cord blood transplant, high risk hematological malignancy